Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Small, midcaps in favour today
Fri, 31 Dec 01:30 pm

Persistent buying activity led the Indian markets to remain firm above the dotted line during the previous hour of trade. Stocks from the realty, banking and consumer durables sectors are leading the pack of gainers at the moment, while those from the IT sector are the sole losers. FMCG and healthcare stocks are amongst the other key underperformers.

The BSE-Sensex is trading higher by 120 points while the NSE-Nifty is up by about 30 points. The BSE Midcap is up by 1.1%, while the BSE Small cap Index is trading higher by 1.3%. The rupee is trading at 44.82 to the US dollar.

Fertilizer stocks are trading in the green with Chambal Fertilizer, Godavari Fertilizer and Madras Fertilizers leading the pack of gainers. Rallis India, a subsidiary of Tata Chemicals, has completed the acquisition of a seeds research firm Metahelix Life Sciences for an all-cash deal of Rs 1 bn. With the acquisition of a majority stake of 53.5% in the Bangalore-based firm, Rallis has become its holding company. The acquisition was aimed at bringing in significant capabilities in seeds segment. The all-cash deal was funded largely through internal accruals. Rallis plans to enhance its stake in the firm up to 100% in five years. Rallis would subscribe to an additional equity of Rs 250 m to take its stake to 59.02% on a fully-diluted basis.

Pharma stocks are currently trading firm Orchid Chemicals, Sterling Biotech, Dishman Pharma. The stock of Sun Pharma has managed to find favour today. This is seemingly on the back of the company receiving a tentative approval from the US FDA (Food and Drug Administration) for a generic version of Roche's Boniva. This drug is believed to be used for the treatment of osteoporosis in postmenopausal women. Considering that this drug has annual sales of US$ 70 m (approximately Rs 3.2 bn) this is a positive development for the company as it throws up bigger opportunities in the US market for the company.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Small, midcaps in favour today". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.